<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393742</url>
  </required_header>
  <id_info>
    <org_study_id>R01AG013038-19</org_study_id>
    <nct_id>NCT02393742</nct_id>
  </id_info>
  <brief_title>Nitrite Supplementation for Improving Physiological Function in Older Adults</brief_title>
  <acronym>NITRITE</acronym>
  <official_title>Efficacy of Oral Sodium Nitrite for Improving Physiological Functions in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Boulder</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Boulder</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nitric oxide (NO) is an essential molecule in the body that decreases with aging and causes&#xD;
      reductions in vascular, movement (&quot;motor&quot;) and cognitive functions. This study will determine&#xD;
      if daily oral supplementation (3 months) with a compound that increases NO in the body, i.e.,&#xD;
      sodium nitrite, improves vascular, motor and cognitive function in older adults. The project&#xD;
      also seeks to provide insight into the biological reasons (mechanisms) by which&#xD;
      supplementation with sodium nitrite improves physiological function in older adults. Overall,&#xD;
      this research will provide scientific evidence supporting the use of sodium nitrite for&#xD;
      preserving physiological function and preventing clinical disease and disability with aging.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular Function</measure>
    <time_frame>3 months</time_frame>
    <description>flow mediated dilation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Motor Function</measure>
    <time_frame>3 months</time_frame>
    <description>rate of torque development</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic oxidative stress and inflammation</measure>
    <time_frame>3 months</time_frame>
    <description>circulating markers of oxidative stress and inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with additional measures of motor ability</measure>
    <time_frame>3 months</time_frame>
    <description>tests of balance, endurance, strength, and dexterity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endothelial cell oxidative stress and inflammation</measure>
    <time_frame>3 months</time_frame>
    <description>inflammatory and oxidative stress markers in biopsied endothelial cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma metabolites</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH Toolbox cognition test battery</measure>
    <time_frame>3 months</time_frame>
    <description>Cognitive Function</description>
  </secondary_outcome>
  <other_outcome>
    <measure>neural activation</measure>
    <time_frame>3 months</time_frame>
    <description>brain activity measured during n-back task in functional magnetic resonance imaging (fMRI)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Ageing</condition>
  <arm_group>
    <arm_group_label>Sodium Nitrite Supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg/day (40 mg 2x/day) slow release sodium nitrite (TheraVasc, Inc) for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 2x/day for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium nitrite</intervention_name>
    <arm_group_label>Sodium Nitrite Supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Age 60-79 years. Women will be confirmed as postmenopausal (either natural or&#xD;
             surgical) based on cessation of menses for &gt;1 year.&#xD;
&#xD;
               -  Ability to provide informed consent&#xD;
&#xD;
               -  Score &gt;22 on the mini mental state exam (MMSE) to allow a broad range of normal&#xD;
                  and mildly-impaired cognitive abilities, but function adequate to understand and&#xD;
                  complete trials (214)&#xD;
&#xD;
               -  Baseline brachial flow-mediated dilation (FMD) &lt; 7%Δ (rationale: non-invasive&#xD;
                  screening to ensure exclusion of subjects with exceptionally high baseline&#xD;
                  endothelial function(215))&#xD;
&#xD;
               -  Blood pressure (BP) &gt;100/60 mmHg for past 3 mo (rationale: blood pressure below&#xD;
                  100/60 mmHg may elevate the normally small risk of hypotension with sodium&#xD;
                  nitrite treatment)&#xD;
&#xD;
               -  Ability to perform motor and cognitive tests (e.g., can rise from a chair, walk&#xD;
                  for 2 min, climb 10 stairs)&#xD;
&#xD;
               -  Willing to accept random assignment to condition (older adults)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • High dietary nitrate intake or current nitrite supplementation; hypersensitivity to&#xD;
             nitrates or nitrites&#xD;
&#xD;
               -  Glucose-6-phosphate dehydrogenase deficiency or blood methemoglobin &gt;2%&#xD;
&#xD;
               -  Current smoking&#xD;
&#xD;
               -  Having past or present alcohol dependence or abuse, as defined by the American&#xD;
                  Psychiatry Association, Diagnostic and Statistical Manual of Mental Disorders&#xD;
&#xD;
               -  Body mass index (BMI) &gt;40 kg/m2 (FMD measurements can be inaccurate in severely&#xD;
                  obese patients)&#xD;
&#xD;
               -  Chronic clinical diseases (e.g., coronary artery/peripheral&#xD;
                  artery/cerebrovascular diseases, diabetes, chronic kidney disease requiring&#xD;
                  dialysis, neurological disorders or diseases that may affect motor/cognitive&#xD;
                  functions [multiple sclerosis, Parkinson's disease, polio, Alzheimer's disease,&#xD;
                  dementia or other brain diseases of aging]), except hypertension and&#xD;
                  hyperlipidemia.&#xD;
&#xD;
               -  Regular vigorous aerobic/endurance exercise (&gt;3 vigorous bouts/week)&#xD;
&#xD;
               -  Not weight stable in the prior 3 months (&gt;2 kg weight change) or unwilling to&#xD;
                  remain weight stable throughout study (rationale: recent weight change or weight&#xD;
                  loss can influence vascular function and small metabolite signature(216))&#xD;
&#xD;
               -  Current treatment or recent cessation (&lt; 3 mo) of hormone replacement therapy.&#xD;
&#xD;
               -  Moderate or severe peripheral artery disease (ankle-brachial index &lt;0.7)(183)&#xD;
&#xD;
               -  A graded exercise test will be performed by all subjects, if there is physician&#xD;
                  concern or an adverse event, the subject will not participate in a maximal oxygen&#xD;
                  consumption test (this will be determined in accordance with stated&#xD;
                  contraindications for exercise testing provided by the American Heart&#xD;
                  Association)(217)&#xD;
&#xD;
               -  Claustrophobia, metal implants, etc., affecting feasibility and/or safety of the&#xD;
                  fMRI scanning.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew J Rossman, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Colorado, Boulder</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douglas R Seals, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Boulder</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Translational Research Center</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.colorado.edu/intphys/research/cardiovascular.html</url>
    <description>description of our laboratory</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 13, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Colorado, Boulder</investigator_affiliation>
    <investigator_full_name>Douglas Seals</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

